查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552865

心臟病诊断市场规模、份额、趋势分析报告：按测试、按最终用途、按地区、细分市场预测，2024-2030 年

Heart Attack Diagnostics Market Size, Share & Trends Analysis Report By Test (Electrocardiogram, Blood Test), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

心臟病诊断市场成长与趋势：

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球心臟病诊断市场规模预计将达到 185.2 亿美元。

预计 2024 年至 2030 年期间，心臟病诊断市场将以 8.2% 的复合年增长率成长。整体风险因素和疾病负担仍然很高，使得心臟病诊断领域具有盈利的成长前景。这种增长主要是由于心臟疾病的高盛行率、吸烟增加、肥胖、不健康饮食的强化以及个体中高胆固醇的发病率，特别是在不断增长的老年人口中。然而，移动心臟门诊遥测心电图（ECG）的医疗保险报销较低以及心臟病发病率的逐渐下降预计将阻碍市场成长。

心臟病诊断市场包括测量心臟电活动的心电图、提供心臟影像的超音波以及测量某些蛋白质（如肌钙蛋白水平和心肌酵素）过度表达的血液测试，按产品分类为「其他」。 。由于技术进步和心电图应用的增加，预计开发中国家的心电图领域将呈现显着成长。然而，对具有成本效益的快速血液检测（如肌钙蛋白和肌酸激酶 MB同功异构酵素(CK-MB)）的需求不断增长，可能会在不久的将来获得显着的市场占有率。本报告涵盖的主要国家包括美国、加拿大、德国、英国、中国、印度、巴西、墨西哥、南非和中东。预计亚太地区将成为预测期内成长最快的地区。同时，北美预计将主导全球心臟病诊断市场。

心臟病诊断市场报告亮点

  • 据估计，北美将主导全球心臟病诊断市场。人们对心臟病及其原因和风险因素的认识不断提高，以及对先进技术诊断的采用和接受程度的提高，预计将有助于市场的成长。
  • 预计亚太地区在预测期内将经历最快的成长。这是因为在印度等某些发展中地区，心臟病负担非常严重，每年有 240 万人死于心臟病。由于心臟病患病率迅速上升，迫切需要采取意识提升的措施并采用先进的诊断方法，预计这将推动市场成长。
  • 肌钙蛋白细分市场在血液检测市场占据主导地位，到 2023 年将占 62.5% 的份额。肌钙蛋白 T 是一种存在于心肌中的蛋白质，对于透过高度敏感的肌钙蛋白 T 测试诊断心臟病至关重要。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章心臟病诊断市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 心臟病诊断市场分析工具
    • 波特的分析
    • PESTEL分析

第 4 章 心臟病诊断市场：透过测试进行的估计和趋势分析

  • 细分仪表板
  • 心臟病诊断市场：测试变异分析，2023 年和 2030 年
  • 心电图
  • 验血
  • 其他的

第五章 心臟病诊断市场：依最终用途分类的估计和趋势分析

  • 细分仪表板
  • 心臟病诊断市场：2023 年和 2030 年最终用途变化分析
  • 医院
  • 门诊手术中心
  • 其他的

第六章 心臟病诊断市场：区域估计与趋势分析

  • 心臟病诊断市场占有率（按地区），2023 年和 2030 年，十亿美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • GE Healthcare
    • Hitachi Corporation
    • Koninklijke Philips NV
    • Midmark Corporation
    • F Hoffmann-La Roche Ltd
    • Schiller AG
    • Siemens Healthineers
    • Toshiba Corporation
    • Welch Allyn Inc
    • Astrazaneca PLC
简介目录
Product Code: GVR-1-68038-053-8

Heart Attack Diagnostics Market Growth & Trends:

The global heart attack diagnostics market size is expected to reach USD 18.52 billion by 2030, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to grow at a CAGR of 8.2% during the forecast year from 2024 to 2030. The overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth.

The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market.

Heart Attack Diagnostics Market Report Highlights:

  • North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.
  • The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.
  • The Troponin segment dominated the blood tests market and accounted for a share of 62.5% in 2023. Troponin T, a protein present in the heart muscle, is crucial in diagnosing heart attacks through a high-sensitivity troponin T test.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Heart Attack Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Heart Attack Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Heart Attack Diagnostics Market: Test Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Heart Attack Diagnostics Market: Test Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Electrocardiogram
    • 4.3.1. Electrocardiogram Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Blood Test
    • 4.4.1. Blood Test Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.1. Troponin
        • 4.4.1.1.1. Troponin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 4.4.1.2. CK-MB
        • 4.4.1.2.1. CK-MB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Others
    • 4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Heart Attack Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Heart Attack Diagnostics Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Hospitals
    • 5.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Ambulatory Surgical Centers
    • 5.4.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Others
    • 5.5.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Heart Attack Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Heart Attack Diagnostics Market Share, By Region, 2023 & 2030, USD Billion
  • 6.2. North America
    • 6.2.1. North America Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3. Europe
    • 6.3.1. Europe Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.2. U.K.
      • 6.3.2.1. U.K. Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.4. France
      • 6.3.4.1. France Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.8. Norway
      • 6.3.8.1. Norway Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.3.9. Sweden
      • 6.3.9.1. Sweden Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.2. China
      • 6.4.2.1. China Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.4. India
      • 6.4.4.1. India Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Latin America
    • 6.5.1. Latin America Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Heart Attack Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.6.4. South Africa
      • 6.6.4.1. South Africa Heart Attack Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Heart Attack Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. GE Healthcare
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Hitachi Corporation
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Koninklijke Philips NV
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Midmark Corporation
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. F Hoffmann-La Roche Ltd
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Schiller AG
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Siemens Healthineers
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Toshiba Corporation
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Welch Allyn Inc
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Astrazaneca PLC
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives